Integration of TCGA and Gene Expression Omnibus (GEO) datasets involving head and neck cancer concluded that EGFR and PTGS2 were identified as important nodes of the immune phenotype-related network in genetic and epigenetic levels, and EGFR inhibition was recommended as a potential target of combination therapy for ICI non-responders [134]. The gene discussed is EGFR; the disease is head and neck cancer.